Live feed00:03:00·737dPRReleasevia QuantisnowImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung CancerByQuantisnow·Wall Street's wire, on your screen.IBRX· ImmunityBio Inc.Health Care
